CorMedix Q1 net income rises to $38.6 million; revenue more than doubled to $127.4 million

CorMedix

CorMedix

CRMD

0.00
  • CorMedix posted net income of USD 38.6 million, up 87% year over year, as revenue more than doubled to USD 127.43 million.
  • Operating income climbed to USD 63.66 million, up 216%, while total operating expenses rose to USD 41.46 million, up 139%.
  • Product sales increased to USD 121.92 million, up more than doubled, including DefenCath sales of USD 97.51 million; contract revenue was USD 5.51 million.
  • Other expense totaled USD 8.01 million, reflecting USD 3.55 million unrealized loss on Talphera equity securities and USD 4.2 million change in contingent consideration.
  • CorMedix flagged a July 1, 2026 shift in DefenCath reimbursement that it expects will significantly reduce net pricing in second-half 2026, while targeting commercialization of REZZAYO in a prophylaxis indication in 2027 if approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410098-26-000021), on May 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.